Christoph Rader

USPTO Granted Patents = 26 (Patent Applications = 15)

CIPO Patents = 3 (Patent Applications = 10)

EPO Patents = 8 (Patent Applications = 15)

Average Co-Inventor Count = 3.5

ph-index = 10

Forward Citations = 727(Granted Patents)

Location History:

San Diego, CA (US) (2001 - 2012)
Olney, MD (US) (2014 - 2016)
Jupiter, FL (US) (2015 - 2024)

Company Filing History:

12 out of 1,187

The Scripps Research Institute

patents

8 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

4 out of 2,597

University of Pennsylvania

patents

4. 3 out of 2,930

University of Florida Research Foundation Inc

H. Lee Moffitt Cancer Center and Research Institute, Inc.

patents

7. 2 out of 1,933

University of South Florida

University of Virginia Patent Foundation

patents

10. 1 out of 289

Fred Hutchinson Cancer Center

patents

11. 1 out of 2

Modulation Therapeutics

patents

12. 3 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2025

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12286487 - Antibody compounds with reactive arginine and related antibody drug conjugates (2025-04-29),

2. 12281167 - Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs) (2025-04-21),

3. 11970525 - Treatment of cancer using GFR alpha-4 chimeric antigen receptor (2024-04-30),

4. 11834501 - ROR2 antibody compositions and related methods (2023-12-05),

5. 11802159 - Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs) (2023-10-31),

6. 11384139 - Antibody targeting cell surface deposited complement protein C3d and use thereof (2022-07-12),

7. 11242388 - ROR1 antibody compositions and related methods (2022-02-08),

8. 11197934 - Dual variable domain immunoconjugates and uses thereof (2021-12-14),

9. 11078273 - ROR2 antibody compositions and related methods (2021-08-03),

10. 11078235 - Cyclic peptide conjugates and methods of use (2021-08-03),

11. 10851149 - Treatment of cancer using GFR α-4 chimeric antigen receptor (2020-12-01),

12. 10618959 - ROR1 antibody compositions and related methods (2020-04-14),

13. 10035848 - Antibody targeting cell surface deposited complement protein C3d and use thereof (2018-07-31),

14. 10011635 - Cyclic peptide conjugates and methods of use (2018-07-03),

15. 9758586 - Chimeric rabbit/human ROR1 antibodies (2017-09-12),

Title: The Innovative Journey of Christoph Rader

Introduction: Christoph Rader, a pioneering inventor based in Jupiter, FL (US), is renowned for his groundbreaking contributions to the field of biotechnology and pharmaceuticals.

Latest Patents: Christoph Rader holds several patents in the areas of targeted cancer therapies and drug delivery systems, with his most recent patent focusing on a novel approach to personalized medicine through genetic targeting.

Career Highlights: With a distinguished career spanning over two decades, Christoph Rader has held key positions in leading research institutions and biotech companies, where he has spearheaded numerous projects that have revolutionized the medical industry.

Collaborations: Throughout his career, Christoph Rader has collaborated with top scientists, researchers, and pharmaceutical companies to develop innovative solutions for complex medical challenges. His collaborative efforts have resulted in the successful development of cutting-edge therapies.

Conclusion: Christoph Rader's relentless pursuit of innovation and his passion for improving healthcare have solidified his position as a trailblazer in the field of biotechnology. His remarkable contributions continue to inspire future generations of inventors and researchers in the quest for groundbreaking medical advancements.

This text is generated by artificial intelligence and may not be accurate.